论文部分内容阅读
对血液学家来说,有效地治疗慢性粒细胞性白血病(CGL)仍是一个棘手的问题。虽然对治疗Ph~1染色体阳性的CGL患者能使其生命状况有所改善,但是用目前的治疗方案对患者的生存期改进不大。CGL在儿童白血病中只占2％～4％,而Ph~1阳性者更为罕见。在成人数组CGL患者中,Ph~1阴性者占10％～20％,这些患者发病的中数年龄为60岁,他们的生存期达18个月。如果儿童发生这种类型的白血病,无疑对化疗反应是差的,且在几个月就死亡。这种所谓幼年型CGL与ph~1阳性的CGL的临床方面有是本质上的不
For hematologists, the effective treatment of chronic myelogenous leukemia (CGL) remains a thorny issue. Although CGL patients who treat Ph-1-positive CGLs have improved their life status, the current treatment regimen does not improve patient survival significantly. CGL accounts for only 2% to 4% of childhood leukemia, whereas Ph-1 positive is even more rare. Among adult CGL patients, Ph ~ 1 negatives account for 10% to 20%. The median age of these patients is 60 years and their survival is 18 months. If a child develops this type of leukemia, the response to chemotherapy is undoubtedly poor, and dies within a few months. The clinical aspects of this so-called juvenile CGL and ph-1-positive CGL are not essential